Announcement PDF ATOMO DIAGNOSTICS FY26 RESULTS OVERVIEW 31 AUGUST 2026 2 This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on information available as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. Reliance should not be placed on the information or opinions contained in this presentation. An investor must not act on the basis of any matter contained in this presentation but should make its own assessment of Atomo as part of its own investigations. This presentation has been provided for general information purposes only. It does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Atomo, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, neither Atomo, nor any of its officers, directors, employees and agents, nor any other person, accepts any responsibility or liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. This disclaimer also extends to all and any information and opinions contained in, and any omissions from, any other written or oral communications transmitted or otherwise made available to the recipient in connection with the opportunity outlined in this presentation and no representation or warranty is made in respect of such information. The information presented in this presentation is subject to change without notice and Atomo does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The cover image is illustrative only. This presentation may contain certain forward-looking statements that are based on Atomo’s beliefs, assumptions and expectations and on information currently available to Atomo management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Atomo to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding present and future business strategies and the business, economic and competitive environment in which they operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. To the full extent permitted by law, Atomo and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation). DISCLAIMER ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 3 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) ATOMO DIAGNOSTICS - FY26 IN REVIEW Financial Highlights • Revenue growth of 41% bringing total revenue for the FY26 of $5.3 million • EBITDA improvement of 39% highlights increasing operating leverage in the business • Cash receipts for the period totaling $10.2 million • Cash on hand of $3.7 million on 30 June 2026 and the company remains debt free • $4.6m from customer receipts • $4.0m from capital raised during the period, net of transaction costs ASX: AT1 Business Highlights • Strong growth in HIV franchise of 21% to $2.8 million • OEM revenue grew 209% to $2.2 million, driven by Lumos Diagnostics launch of CLIA-waived FebriDx • Onboarded Pharmacies in Australia selling the Atomo HIV Self- Test increases 56% during the year plus July 2026 (from 126 to 196 – more growth anticipated during FY27) • Active syphilis technical product development completed, commencing with analytical and clinical studies in FY27 • Successful completion of Pascal orders received Jan 2026 for two new OEM customers – supports long-term supply agreements; anticipated early in FY27 • Commencing development efforts for ATL Liver function test - focus initially on liver function monitoring for patients prescribed at-risk drugs and fatty liver disease screening Transitioning to sustainable revenue growth with an expanding new product pipeline 4 NEW CHAPTER FOR ATOMO – FROM FOUNDATION TO GLOBAL SCALE • Building on 15 years of innovation and execution under founder and long-standing CEO John Kelly • A seamless leadership transition designed to preserve institutional knowledge while bringing global commercial focus • Dr. Cheri Walker appointed Interim CEO, with extensive experience across life sciences, diagnostics and international commercialisation • Leadership positioned closer to Atomo's key growth markets, particularly the US and Europe • Strategic priority shifts from foundation- building to scale: accelerating adoption, expanding partnerships and maximising the value of Atomo's differentiated platform Passing the baton from founder leadership to the next phase of commercial growth 5 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) REFLECTIONS ON FY26 Accelerating growth: 41% FY26 revenue growth, reflecting strong momentum across the business Improving economics: Continued improvement in EBITDA (+39% YOY) as scale, mix and operational discipline strengthen the underlying business Capital discipline: Prudent cash management while maintaining the investment required for innovation and to support growth Multiple growth engines: Increasing contribution from core HIV, OEM/Pascal and emerging product opportunities reduces reliance on any single revenue stream Visible runway: Existing customer relationships, expanding distribution and new product launches provide a foundation for continued FY27+ growth Pipeline creates future optionality: New products expand the addressable market and create additional platforms for future revenue Long-term value creation: Building a growing, diversified revenue base that can fund innovation and compound enterprise value over time FY26 established the foundation for Atomo's next phase of value creation 6 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) WHO IS ATOMO? WHATBUSINESSESDOWE HAVE? • We are a commercial stage diagnostic company with a growing revenue base from sales of approved professional and self-test point-of-care tests (POCT) across global markets • Atomo solutions deliver unmatched usability and reliability that enable decentralised testing, a trend jump-started during the pandemic and now driven by global changes in rapid testing requirements and where timely centralised testing is not available • Atomo is poised for significant growth with proven products in themarket, a growing pipeline of products in development, and established partners launching exciting newPOCTproducts across global markets Diagnostic company with a growing portfolio of patented rapid tests with proven superior usability, reliability, and performance Atomo Point of Care Test (POCT) Diagnostic Products: • Blood-based rapid tests sold into professional use and self-test market channels on a global basis • Focus on growing our pipeline of high value, reimbursed diagnostic products for decentralised professional testing Point of Care Test Technologies (OEM Business): • Growing partner sales driven by an FDA approved/CLIA waived test positioned for professional use, decentralised testing • Integrated proprietary all-in-one device for partners seeking improved usability and performance for blood-based POCT • Additional technologies that can integrate with the client’s own cassette, turning it into a user-friendly system for blood-based POCT WHO IS ATOMO AND WHAT DO WE DO? ASX: AT1 Commercial-stage diagnostic products company with a growing a portfolio of innovative point-of-care rapid tests for global markets TESTS UNDER CONSIDERATION Stroke Acute neurological triage HCV Hepatitis B Virus HIV Gen 4 4th generation HIV detection Cardiac Subject to commercial assessment ATOMO’S OWN DIAGNOSTIC PRODUCT PIPELINE ASX: AT1 HBV Hepatitis C Virus Pipeline focused on global professional use markets disseminating rapid testing to urgent care and other decentralised opportunities ASX: AT1 Expanding sales from attractive OEM business with products ranging from launched to new ones entering the pipeline ASX: A1 PARTNER PORTFOLIO UPDATES UK Customer • Atomo is partnering with a UK company on a novel rapid test that addresses a large unmet clinical need in professional settings. • In FY26, 20,000 Pascal units ordered to support validation and registration requirements. Commercial supply agreement for Pascal anticipated in early FY27. Ferritin – New Product Opportunity • Atomo has partnered with Chromacare to develop a rapid test for measuring iron levels, with applications in both professional and at home self test markets. Initial order received this year from Chromacare worth ~A$170,000. FebriDx Market Launch Continues • Atomo partner Lumos Diagnostics received CLIA waiver of its FebriDx product, which uses Atomo’s Pascal device for rapid, blood-based testing to differentiate bacterial versus non- bacterial infection. US clinical trials validated greater than 99% concordance between trained and untrained users. The target market includes urgent care and other reimbursed decentralised professional use testing. • Atomo received FY26 orders for FebriDx totaling ~A$1.9 million, representing a nine-fold increase when compared to the prior year. 9 FY26 – REVENUE SUMMARY ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) Strong sales growth across core activities in HIV Tests and Pascal OEM Revenue growth across core activities • HIV Growth 21% YoY, totaling $2.8 million • OEM Growth 209% YoY, totaling $2.2 million • Overall total revenue* growth 41% YoY bringing total FY26 revenue to $5.3 million - 0.50 1.00 1.50 2.00 2.50 3.00 HIV OEM A$'m Revenue YoY Growth Jun-25 Jun-26 * Total revenue includes development and other income HIV BUSINESS ACTIVITY ASX: AT1 NFLD (Europe) Australian Pharmacy Growing Momentum • 196 pharmacies active in Australia • Target to grow 6x over the next 3 years • 59 new pharmacies added in FY26 New Zealand – Expansion and foundation established • 73 pharmacies activated since launch in FY25 • Target to grow 8x over the next 3 years • CDC (Pharmacy Wholesaler) commenced ordering towards end of FY26 Australia Government Program • Rollover order from key government programs • NAPWHA demand has grown 275% over the last 24 months International HIV Business Significant growth underway across European and LMIC markets ATOMO DIAGNOSTICS LIMITED | ASX: AT1 | Q4 FY2026 QUARTERLY REPORT | JULY 2026 Viatris (LMIC) Revenue up 69% YoY Revenue up 74% YoY Continued push on growing HIV sales is paying off in 21% YOY growth in HIV sales ACTIVE SYPHILIS – ADVANCING THROUGH THE PIPELINE • no existing rapid test can reliably distinguish active & prior infection • no current test format is optimised for easy, reliable self-testing Channel Leverage — Similar users, public buyers and distribution channels Addressing significant unmet clinical and market needs Efficiency — Lower cost of entry, faster time to launch and scale revenue Established demand via existing HIV channels Development & Commercial Readiness: • Product Development & Initial Verification Complete Strong product verification and preliminary clinical data supporting commercial interest Sensitivity greater than 85% for active syphilis detection is market leading • Technology Transfer commenced for Manufacturing (Q4 FY26 and Q1 FY27) Enabling product for formal clinical trials and reg. submissions and validating manufacturing processes • Clinical Trials commencing early CY27 Clinical validation planning underway and progressing toward commercialisation • Initial engagement with Regulator successfully completed Positive engagement with clinicians and key stakeholders to support market access ASX: AT1 Successful completion of product development preparing for clinical trials in early CY27 11 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) ALT LIVER TEST – ENTERS THE DEVELOPMENT PIPELINE Commercial pathway: Confirming priority use case for clinical-trials and doctor prescribed at-home liver monitoring Partner development: Engage with pharmaceutical, CRO or commercial partners during FY27 KOL engagement: Engagement commenced with clinical leaders in key channels – DILI / pharmaceutical conferences and Fatty Liver disease KOLs Partner development: Engage with Australian clinical KOL’s and public health to assess use of a screening test across high-risk cohorts for Fatty Liver disease Assess funding opportunities for this application: Fatty Liver disease has a very large public health cost globally generating interest from governments Unique, large product opportunity for detecting liver damage 13 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) • Atomo received FY26 orders for FebriDx totaling ~A$1.9m, representing a nine- fold increase in Pascal FebriDx orders when compared to FY25 • Lumos signed a six-year agreement with PHASE Scientific for supply of FebriDx® in US - Lumos anticipates FebriDx product revenues of up to US$317 million over the term, assuming CLIA waiver is granted and contracted MOQ’s achieved • FebriDx® received CLIA waiver from the US FDA, based on Pascal performance - validated in US trials as delivering greater than 99% concordance between trained and untrained users • Each FebriDx® test sold to Phase requires Lumos order a Pascal cassette, with Atomo receiving a percentage portion of the proceeds based on the transfer price of Pascal FEBRIDx – FY26 HIGHLIGHTS 2026 and future revenue growth driven by Lumos Diagnostics CLIA waiver, sales focus, and distribution partnership 14 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) CHROMACARE – FERRITIN OPPORTUNITY Rapid Test to screen for Iron Deficiency in Point-of-Care Other Tests in active development • Atomo has partnered with Canadian company Chromacare on a rapid test that can measure iron levels (Ferritin), with applications in both professional and at home self test markets. Initial order received this quarter from Chromacare worth ~A$170,000 • Pascal units supplied to support product validation and registrations – long term commercial supply agreement for Pascal anticipated in early FY27 • Chromacare interest in a US CLIA waiver submission supported by Pascal and utilising Pascal FebriDx as a predicate Another high value product targeted to the professional use, decentralised testing market 15 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) UK Customer • Atomo is partnering with a UK company on a novel rapid test that addresses a large unmet clinical need in professional settings • 20,000 Pascal units ordered to support validation and registration requirements. Commercial supply agreement for Pascal anticipated in early FY27 Promotion post CLIA waiver • Atomo is implementing market engagement and partnering with a number of US test development companies on promotion of Pascal as a proven solution for rapid blood test assays seeking expanded market access through CLIA waiver approval in the US* or launching as a self test * CLIA waiver approval typically increases the addressable market for a rapid blood test >10-fold https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02979439- 2A1614136&v=4a466cc3f899e00730cfbfcd5ab8940c41f474b6 Successful completion of manufacture of products for feasibility study UK CLIENT – EXCITING NEW POCT PRODUCT CATEGORY FY26 OPERATIONAL UPDATE ASX: AT1 Execution on important steps to increase resilient capacity and improve gross margins Operational expansion initiated to support the growth of Atomo Diagnostic Products and OEM Pascal units • Increased production capacity and improved margins on supply of Pascal to customers and for use in Atomo finished diagnostic tests • Qualification underway of high cavitation injection mould tooling to increase component capacity and reduce Cost of Goods (COGs) • Qualification of the company’s proprietary high volume Blister Machine #2 – now located in an Atomo operated facility in Sydney • Expansion of Finished Test Assembly / Packaging accreditation at Atomo’s South Africa beyond HIV to include supply of Active Syphilis tests • Blister Machine 2 was successfully relocated to an Atomo-operated facility in Sydney. The facility will be integrated into Atomo’s Quality Management System (QMS) in the coming months ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 16 FY 2026 FINANCIALS 18 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) FY26 PROFIT & LOSS • Revenue up 41%, driven by strong volume demand across HIV Global Health Market • Gross margin lower due to product mix • Prior including net ~$340k in one-off license fees, impacting margin by 6% YoY • Core product margin excluding licence and developments fees was 35% vs 42% YoY. • Shift driven by higher product demand from lower yielding Global Health market segments • Operational discipline with overall expense reducing YoY $640k/+9%. • Investment in R&D activities further offset eligible operational costs during the period. Net improvement of $1.34m/+25% YoY. • Underlying EBITDA improved 39% from a loss of $3.38m to a loss of $2.06m, representing a meaningful step towards profitability AUD FY26 ($m) FY25 ($m) (%) Revenue 5.33 3.79 41% Cost of sales (3.45) (1.87) Gross Profit 1.88 1.92 (2%) Gross Margin 35% 51% Other income 2.24 1.52 47% Employee benefits expense (2.88) (3.26) 12% Foreign exchanges gains/(losses) (0.04) (0.01) (300%) Research and development costs (0.76) (0.62) (23%) Professional fees expense (0.49) (0.95) 48% Inventory obsolescence expense (0.12) (0.13) 8% Other expenses (1.89) (1.85) (2%) Underlying EBITDA (2.06) (3.38) 39% Strong revenue growth and improving EBITDA while investing in innovative R&D development and pipeline • Cash and cash equivalents of $3.71m at 30 June 2026, and remaining debt free • During the year, the Atomo completed capital raisings of $4.0m net of transaction costs, provide funding to support ongoing commercialisation, product development and funding future growth initiatives. • Capitalised expenditure relating to R&D and PPE for the period was not significant • Atomo’s balance sheet supports ongoing investment in portfolio expansion, pipeline development opportunities and cost of goods reduction initiatives, aimed at driving future revenue growth and improving margins. 19 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) FY26 BALANCE SHEET AUD FY26 ($m) FY25 ($m) Cash and cash equivalents 3.71 3.22 Trade and other receivables 3.22 1.69 Inventories 1.97 1.65 Property, plant and equipment 0.34 0.89 Intangible assets 1.22 1.64 Other assets 0.36 0.18 Total assets 10.82 9.27 Trade and other payables 1.68 1.02 Other liabilities 1.43 1.28 Total liabilities 3.11 2.30 Net Assets 7.71 6.97 Finishing the year with a solid cash position and no debt • Total Cash receipts: $10.2m • ~$4.6m from customer receipts • $875k from R&D tax rebate • $660k from CRC-P grant for Syphilis test development • ~4m from capital raised during the period, net of transaction costs • Total Cash payments: $9.7m • $4.1m in stock purchases • $5.6m in operating expenses • Year-end cash balance of $3.7m, no debt 20 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) FY26 CASHFLOW A$m 0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 Strong cash generation from sales, grants, and fundraising activities Revenue Operating Discipline EBITDA Productive Assets FY25 Revenue A$3.8M ✓ Atomo is seeing strong momentum in its established revenue channels including HIV Testing and Pascal OEM ✓ Expansion of customer base across new partners for Pascal and an expanded Atomo test product pipeline FY26 Revenue A$5.3M +40% GROWTH ✓ Capital focus on new test portfolio development / commercialisation – Syphilis and Liver ✓ Non-dilutive funding grants (Syphilis) and selective licensing of proven assets (Liver) used to support lower-cost development and go to market -5 -4.5 -4 -3.5 -3 -2.5 -2 -1.5 -1 -0.5 0 FY24 FY25 FY26 A$(m) Historical EBITDA ✓ EBITDA – continued trend towards breakeven as existing revenue channels grow and product offerings expand ✓ Debt free balance sheet ✓ Atomo validating a second-generation blister machine and high-cavity mould tooling to support expansion of capacity and improve economies of scale and margins ASX: AT1 FINANCIAL SUMMARY 21 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) FY2026 was a transitional year, showing strong and sustainable revenue growth with improving EBITDA 22 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) FY26: YEAR OF TRANSITION Strong revenue momentum: FY26 revenue growth of 41%, demonstrates increasing demand across Atomo's core business lines and emerging opportunities Improving operating leverage: EBITDA performance continued to improve as revenue growth increasingly flows through the business A business increasingly positioned for scale: Revenue growth is becoming broader-based, with momentum across HIV, OEM/Pascal and emerging diagnostic opportunities Confidence in sustainable growth: We expect the underlying revenue trajectory to continue into FY27 and beyond, supported by multiple complementary growth engines Reinvesting growth into innovation: As revenue increases, it is expected to cover most non-research operating costs, providing the opportunity to selectively reinvest in R&D and product development for an attractive future return on investment Expanding the product pipeline: Investment in new tests and applications can broaden Atomo's addressable markets and create additional exciting and significant commercial opportunities Creating a compounding value proposition: Revenue growth → improved operating leverage → reinvestment in R&D → broader product portfolio → longer-term revenue growth and enterprise value Building a platform for sustainable growth : AT1 For further information, please contact: Cheri Walker, Interim CEO and Executive Director Cheri.Walker@atomodiagnostics.com p. +61 2 9099 4750 Investor Queries Investorqueries@atomodiagnostics.com Atomo Strategy Update and FY26 Full Year Investor Webinar Presentation Atomo Diagnostics Limited will hold its Strategy Update and FY26 Full Year Investor webinar on Thursday 24th September 2026. Registration and access details will be released to the ASX and made available to investors in due course. ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)